![]() |
Name |
trans-2-Tetradecene
|
Molecular Formula | C14H28 | |
IUPAC Name* |
(E)-tetradec-2-ene
|
|
SMILES |
CCCCCCCCCCC/C=C/C
|
|
InChI |
InChI=1S/C14H28/c1-3-5-7-9-11-13-14-12-10-8-6-4-2/h3,5H,4,6-14H2,1-2H3/b5-3+
|
|
InChIKey |
OBDUMNZXAIUUTH-HWKANZROSA-N
|
|
Synonyms |
trans-2-tetradecene; (E)-2-Tetradecene; 2-Tetradecene, (E)-; 2-Tetradecene, (2E)-; 2-Tetradecene; P8X235058H; Tetradecylene; N-Tetradecene; (2E)-2-Tetradecene; UNII-P8X235058H; HSDB 5169; UNII-5R30W51348; I(2)-tetradecene; 26952-13-6; EINECS 248-130-9; EC 248-130-9; 1652-97-7; 35953-54-9; 5R30W51348; Q27286388
|
|
CAS | 26952-13-6 | |
PubChem CID | 5352912 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 196.37 | ALogp: | 7.0 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 14 | QED Weighted: | 0.311 |
Caco-2 Permeability: | -4.645 | MDCK Permeability: | 0.00001360 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.506 |
30% Bioavailability (F30%): | 0.987 |
Blood-Brain-Barrier Penetration (BBB): | 0.331 | Plasma Protein Binding (PPB): | 99.85% |
Volume Distribution (VD): | 5.263 | Fu: | 2.08% |
CYP1A2-inhibitor: | 0.783 | CYP1A2-substrate: | 0.212 |
CYP2C19-inhibitor: | 0.525 | CYP2C19-substrate: | 0.082 |
CYP2C9-inhibitor: | 0.262 | CYP2C9-substrate: | 0.953 |
CYP2D6-inhibitor: | 0.388 | CYP2D6-substrate: | 0.125 |
CYP3A4-inhibitor: | 0.266 | CYP3A4-substrate: | 0.071 |
Clearance (CL): | 4.27 | Half-life (T1/2): | 0.127 |
hERG Blockers: | 0.052 | Human Hepatotoxicity (H-HT): | 0.019 |
Drug-inuced Liver Injury (DILI): | 0.079 | AMES Toxicity: | 0.004 |
Rat Oral Acute Toxicity: | 0.016 | Maximum Recommended Daily Dose: | 0.144 |
Skin Sensitization: | 0.948 | Carcinogencity: | 0.033 |
Eye Corrosion: | 0.994 | Eye Irritation: | 0.963 |
Respiratory Toxicity: | 0.318 |